What is Noble Financial’s Forecast for CVKD Q3 Earnings?

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities researchers at Noble Financial issued their Q3 2026 earnings estimates for shares of Cadrenal Therapeutics in a research report issued to clients and investors on Monday, August 17th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.94) for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.37) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.91) EPS and FY2027 earnings at ($3.55) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its earnings results on Thursday, August 13th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.28.

A number of other brokerages have also commented on CVKD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Stock Performance

Shares of NASDAQ CVKD opened at $1.71 on Wednesday. Cadrenal Therapeutics has a 52-week low of $1.64 and a 52-week high of $14.64. The firm has a 50 day moving average price of $2.61 and a two-hundred day moving average price of $4.72. The stock has a market cap of $5.84 million, a P/E ratio of -0.35 and a beta of 1.84.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. DRW Securities LLC bought a new stake in shares of Cadrenal Therapeutics during the 4th quarter valued at about $171,000. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics in the third quarter worth approximately $274,000. JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics in the third quarter worth approximately $103,000. Finally, Geode Capital Management LLC lifted its stake in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the period. 7.92% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Quang X. Pham sold 12,996 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $3.94, for a total value of $51,204.24. Following the transaction, the chief executive officer owned 136,381 shares in the company, valued at $537,341.14. The trade was a 8.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 87,726 shares of company stock worth $333,575 over the last ninety days. 14.59% of the stock is owned by company insiders.

Key Stories Impacting Cadrenal Therapeutics

Here are the key news stories impacting Cadrenal Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2028 EPS forecast to a loss of $1.92 from a loss of $2.33, suggesting the analyst expects longer-term losses to narrow as the company progresses toward potential commercialization or revenue generation.
• Positive Sentiment: Noble Financial’s FY2026 EPS estimate of a $3.91 loss is less pessimistic than the broader consensus estimate of a $4.37 loss. Noble also projects losses improving to $3.55 per share in FY2027, although the company would remain deeply unprofitable.
• Neutral Sentiment: Noble Financial expects Cadrenal Therapeutics to post losses of $0.94 per share in Q3 2026 and $0.89 per share in Q4 2026, with additional quarterly losses of $0.88 to $0.93 projected throughout 2027. These estimates point to ongoing operating expenses without near-term profitability.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a $3.92 loss from $3.19 and cut its FY2027 forecast to a $3.26 loss from $3.09. The firm also lowered its Q3 2026 estimate to a $0.93 loss from $0.65 and its Q4 estimate to a $0.87 loss from $0.75. The downward revisions indicate weaker expected financial performance.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.